Cargando…
Quantities of CD3+, CD8+ and CD56+ lymphocytes decline in breast cancer recurrences while CD4+ remain similar
BACKGROUND: Much is known about tumor infiltrating lymphocytes (Tils) in primary breast cancer, as this has been the focus of much research in recent years, but regarding recurrent breast cancer, only few studies have been done. Our aim was to compare the quantities of Tils in primary breast carcino...
Autores principales: | Mutka, Minna, Joensuu, Kristiina, Eray, Mine, Heikkilä, Päivi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830729/ https://www.ncbi.nlm.nih.gov/pubmed/36627701 http://dx.doi.org/10.1186/s13000-022-01278-5 |
Ejemplares similares
-
Core needle biopsies alter the amounts of CCR5, Siglec-15, and PD-L1 positivities in breast carcinoma
por: Mutka, Minna, et al.
Publicado: (2023) -
Clever-1 positive macrophages in breast cancer
por: Mutka, Minna, et al.
Publicado: (2022) -
Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion
por: Mehraban, Zahra, et al.
Publicado: (2022) -
Alterations in the CD56(−) and CD56(+) T Cell Subsets during COVID-19
por: Vavilova, Julia D., et al.
Publicado: (2023) -
Diagnostic Challenges of CD4(+)/CD56(+)/CD123(+) hematological neoplasms
por: Thiago, Leandro S., et al.
Publicado: (2013)